Here’s what you should know:
1. CSA has two cryospray platforms, truFreeze and Rejuvenair. Physicians use the truFreeze spray in Barrett’s esophagus and esophageal cancer treatments. Rejuvenair is for chronic obstructive pulmonary disease.
2. Horizon Technology Finance provided the most funding: $15 million in venture loan facility funding and $8 million in equity investment.
3. CSA Medical Executive Chairman Vincent Owens said, “Thanks to the support of our existing investors and new partner Horizon, we will continue to expand the market for truFreeze to treat the full spectrum of esophageal diseases including cancer, and we will continue to advance Rejuvenair to improve quality of life for COPD patients.”
More articles on gastroenterology:
North Carolina finalizes plan that could spur ASC, hospital developments — 5 takeaways
Envision Healthcare (AmSurg) fights back on false billing claims & more — 8 ASC company key notes
114 ASC benchmarks to know | 2018
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
